2. Signaling Pathways
  3. Neuronal Signaling
  4. α-synuclein
  5. α-synuclein Inhibitor

α-synuclein Inhibitor

α-synuclein Inhibitors (51):

Cat. No. Product Name Effect Purity
  • HY-157806
    α-Synuclein inhibitor 12
    		Inhibitor
    α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of α-Syn (α-synuclein) aggregation and can be used in the study of neurological diseases.
  • HY-147669
    α-Synuclein inhibitor 7
    		Inhibitor
    α-Synuclein inhibitor 7 (compound 3gf) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.95 μM and inhibition ratio at 30 μM of 85.8%.
  • HY-147644
    α-Synuclein inhibitor 3
    		Inhibitor
    α-Synuclein inhibitor 3 (Compound 7g) is a α-synuclein (α -Syn) aggregation inhibitor. α-Synuclein inhibitor 3 can be used for Parkinson’s disease research.
  • HY-163519
    α-Synuclein inhibitor 13
    		Inhibitor
    α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research.
  • HY-147667
    α-Synuclein inhibitor 5
    		Inhibitor
    α-Synuclein inhibitor 5 (compound 4aa) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.22 μM and inhibition ratio at 30 μM of 94.3%.
  • HY-159152
    PQM-164
    		Inhibitor
    PQM-164 (Compound 3e) has antioxidant activity (IC50: 0.93 μM for DPPH radical). PQM-164 shows anti-inflammatory activity against 6-OHDA (HY-B1081A)-induced neuronal damage in activated microglial cells. PQM-164 decreases the accumulation of α-synuclein. PQM-164 promotes nuclear translocation of Nrf2 and its transcriptional activity. PQM-164 can be used for research of Parkinson’s disease.
  • HY-149065
    D-685
    		Inhibitor
    D-685, a prodrug of D-520, exhibits higher in vivo anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model than the parent D-520. D-685 reduces accumulation of human α-synuclein (α-syn) protein. D-685 exhibits facile brain penetration.
  • HY-121252A
    Dopal (purity>80%)
    		Inhibitor
    Dopal (purity>80%) is an aldehyde that can be generated in Parkinson's disease by enzymatic degradation of dopamine. Dopal (purity>80%) can generate reactive oxygen species (ROS), and triggers aggregation of α-synuclein. Dopal (purity>80%) elicits α-synuclein accumulation and hampers α-synuclein clearance in primary neurons.
  • HY-130398
    Aerophobin-2
    		Inhibitor
    Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of α-synuclein (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy.
  • HY-163613
    NS163
    		Inhibitor
    NS163 is a α-Synuclein aggregation antagonist. NS163 can be used for study of Parkinson’s disease.
  • HY-169198
    GSD-16-24
    		Inhibitor
    GSD-16-24 is a lead compound that binds directly to the C-terminal IDR of α-syn monomers and fibrils, thereby preventing fibrils from binding to the receptor. GSD-16-24 can be used in Parkinson's research.